Caris Life Sciences Inc [CAI] stock is trading at $29.49, up 5.17%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The CAI shares have gain 8.98% over the last week, with a monthly amount glided 11.12%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Caris Life Sciences Inc [NASDAQ: CAI] stock has seen the most recent analyst activity on July 14, 2025, when Wolfe Research initiated its Outperform rating and assigned the stock a price target of $32. Previously, TD Cowen started tracking the stock with Buy rating on July 14, 2025, and set its price target to $32. On July 14, 2025, JP Morgan initiated with a Overweight rating and assigned a price target of $31 on the stock. Guggenheim started tracking the stock assigning a Buy rating and suggested a price target of $32 on July 14, 2025. Evercore ISI initiated its recommendation with a Outperform and recommended $33 as its price target on July 14, 2025. Citigroup started tracking with a Buy rating for this stock on July 14, 2025, and assigned it a price target of $34. In a note dated July 14, 2025, BTIG Research initiated an Buy rating and provided a target price of $38 on this stock.
Caris Life Sciences Inc [CAI] stock has fluctuated between $25.40 and $33.41 over the past year. Currently, Wall Street analysts expect the stock to reach $32 within the next 12 months. Caris Life Sciences Inc [NASDAQ: CAI] shares were valued at $29.49 at the most recent close of the market. An investor can expect a potential return of 8.51% based on the average CAI price forecast.
Analyzing the CAI fundamentals
Caris Life Sciences Inc [NASDAQ:CAI] reported sales of 452.50M for the trailing twelve months, which represents a growth of 49.90%. Gross Profit Margin for this corporation currently stands at 0.63% with Operating Profit Margin at 0.47%, Pretax Profit Margin comes in at 0.28%, and Net Profit Margin reading is 0.09%. To continue investigating profitability, this company’s Return on Assets is posted at 0.01, Equity is 0.04 and Total Capital is 0.06. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of2.49.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, Caris Life Sciences Inc’s Current Ratio is 1.10. As well, the Quick Ratio is 0.70, while the Cash Ratio is 0.17. Considering the valuation of this stock, the price to sales ratio is 18.11.
Transactions by insiders
Recent insider trading involved Denton John Russel, that happened on Jun 20 ’25 when 7500.0 shares were purchased. Brille Brian J completed a deal on Jun 20 ’25 to buy 30000.0 shares.
